专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023088284A1 一种自微乳组合物和制剂及其用途审中-公开
公开(公告)号：WO2023088284A1
公开(公告)日：2023-05-25
申请号：PCT/CN2022/132168
申请日：2022-11-16
申请人：湖南慧泽生物医药科技有限公司
发明人：易木林
IPC分类号： A61K31/47 , A61K9/107 , A61K47/26 , A61K47/14 , A61K47/10 , A61P35/00
摘要：一种自微乳组合物，以质量百分比计，包含0.5-20%的激酶抑制剂脂溶性盐、5-70%油相、5-80%乳化剂和0-50%助乳化剂。通过将激酶抑制剂（例如卡博替尼）制成溶解度显著提高的盐，再以该盐作为活性组分，选择使用特定种类和用量比例的油相、乳化剂和助乳化剂等辅料，使得制备得到的激酶抑制剂（例如卡博替尼）的自微乳组合物具有改善的生物利用度和溶出度。

2. 发明申请

WO2023081253A1 COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS 审中-公开
公开(公告)号：WO2023081253A1
公开(公告)日：2023-05-11
申请号：PCT/US2022/048770
申请日：2022-11-03
申请人： EXELIXIS, INC.
发明人： SHAH, Khalid , DEMORIN, Frenel , SHAKYA, Sagar , WANG, Yong , XU, Wei
IPC分类号： C07D215/48 , A61K31/47
摘要： The present disclosure relates to tyrosine kinase inhibitors of Formula I and Compound 1, or pharmaceutically acceptable salts thereof. The present disclosure further relates to processes for the preparation of the tyrosine kinase inhibitors, Formula I and Compound 1, or a pharmaceutically acceptable salt thereof.

3. 发明申请

WO2023068839A1 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 안정성이 개선된 필름코팅 정제 审中-公开
公开(公告)号：WO2023068839A1
公开(公告)日：2023-04-27
申请号：PCT/KR2022/016031
申请日：2022-10-20
申请人： 한화제약주식회사
发明人： 채유병 , 신서영 , 임채용 , 김진보
IPC分类号： A61K9/24 , A61K9/20 , A61K47/20 , A61K47/12 , A61K9/28 , A61K31/47 , A61K31/495
摘要： 본 발명은 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 제1 약물층; 레보세티리진 또는 이의 약학적으로 허용가능한 염을 포함하는 제2 약물층; 상기 제1 약물층과 일 측면에서 접촉하고, 상기 제2 약물층과 다른 측면에서 접촉함으로써, 상기 제1 약물층과 제2 약물층이 비접촉되게 하는 내층; 및 상기 제1 약물층, 내층 및 제2 약물층을 포함하는 외층을 포함하는 정제 및 이의 제조방법을 제공한다. 본 발명의 몬테루카스트 및 레보세티리진이 단일 정제에 존재하면서도 경계층에 의해 비접촉되는 정제는 제약 분야에서 약물 상호작용이 최소화되면서도 효율적인 방법으로 제조될 수 있는 복합제제로서 유용하게 사용될 수 있다.

4. 发明申请

WO2023041657A1 ALKYLATED HALOQUINOLINES FOR USE IN EPILEPSY 审中-公开
公开(公告)号：WO2023041657A1
公开(公告)日：2023-03-23
申请号：PCT/EP2022/075665
申请日：2022-09-15
申请人： KATHOLIEKE UNIVERSITEIT LEUVEN
发明人： THEVISSEN, Karin , CAMMUE, Bruno , NY, Annelii , LAGAE, Lieven , DE WITTE, Peter
IPC分类号： A61K31/47 , A61K31/137 , A61P25/08 , A61P25/12
摘要： The invention relates to alkylated haloquinolines for use in the prevention or treatment of a seizure in epilepsy or in neuroinflammation associated with epilepsy.

5. 发明申请

WO2023023853A1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS FOR USE AS THERAPEUTICS 审中-公开
公开(公告)号：WO2023023853A1
公开(公告)日：2023-03-02
申请号：PCT/CA2022/051275
申请日：2022-08-23
申请人： THE UNIVERSITY OF BRITISH COLUMBIA
发明人： THAPER, Daksh , ZOUBEIDI, Amina , MUNUGANTI, Ravi
IPC分类号： C07D277/82 , A61K31/47 , A61K31/428 , A61K31/4184 , A61K31/4439 , A61P35/00 , C07D417/12 , C12N5/09
摘要： This invention provides compound having a structure of Formula (I)or (II): (I, II ) and uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provide. Furthermore, the compounds described herein may be used for the treatment of BRN2 expressing cancers. The cancer selected from prostate cancer; lung cancer; bladder cancer; sarcoma; glioma; and melanoma.

6. 发明申请

WO2023021305A1 AQUEOUS WOUND HEALING FORMULATION 审中-公开
公开(公告)号：WO2023021305A1
公开(公告)日：2023-02-23
申请号：PCT/GB2022/052157
申请日：2022-08-19
申请人： ADVANTICE HEALTH, LLC , MCNEENEY, Stephen Phillip
发明人： SPANJER, Hellen , RIVERA, Kathryn Jill , MAIDA, Stephen , LIBRIZZI, Joseph , D'OVIDIO, Anthony
IPC分类号： A61L26/00 , A61K9/00 , A61K31/055 , A61K31/14 , A61K31/167 , A61K36/61 , A61K47/34 , A61K47/36 , A61P17/02 , A61K31/155 , A61K31/245 , A61K31/47 , A61K31/573 , A61K36/886 , A61K36/53 , A61K36/288 , A61K36/28
摘要： The present invention relates to a water resistant wound cover with high comfort and good air permeability. In particular, the present invention relates to an aqueous wound healing formulation comprising a water-soluble or a water-dispersible polymeric material that does not sting when applied to a minor injury to the skin.

7. 发明申请

WO2023016562A1 多环类化合物及其用途审中-公开
公开(公告)号：WO2023016562A1
公开(公告)日：2023-02-16
申请号：PCT/CN2022/112259
申请日：2022-08-12
申请人：浙江同源康医药股份有限公司
发明人：梁阿朋 , 李钧 , 吴豫生 , 陈少卿 , 刘广斌 , 尹洲 , 董胜利 , 李美华
IPC分类号： C07D215/48 , C07D471/04 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/06 , C07D241/44 , C07D487/04 , A61K31/4704 , A61K31/4709 , A61K31/47 , A61K31/4745 , A61K31/498 , A61K31/55 , A61K31/5377 , A61K45/06 , A61P35/00 , A61P35/02
摘要：本发明涉及多环类化合物及其用途。具体地，本发明化合物具有式I所示结构，其中各基团和取代基的定义如说明书中所述；本发明还公开了所述化合物的制备方法及其在调节和治疗与YAP/TEAD的异常活性所导致的相关疾病方面的用途。

8. 发明申请

WO2023012247A1 METHOD OF SPERM SORTING USING LIPOSOMES AND/OR AN INHIBITOR OF SLO3 POTASSIUM CHANNEL 审中-公开
公开(公告)号：WO2023012247A1
公开(公告)日：2023-02-09
申请号：PCT/EP2022/071882
申请日：2022-08-03
申请人： UNIVERS 2020
发明人： CARION, Olivier , SCHMITT, Eric
IPC分类号： C12N5/076 , A01N1/02 , A61D19/02 , A61K31/47
摘要： The invention relates to a method of sperm sorting of the spermatozoa contained in the sperm of a mammalian species, said method comprising a step of mixing the sperm sample with liposomes and/or at least one inhibitor of Slo3 potassium channel. In particular, the invention also relates to a method of sperm sorting of the spermatozoa contained in the sperm of a mammalian species, said method comprising the following steps: - mixing said sperm and a fluorescent dye for labelling sperm DNA with a sample fluid into a fluid mixture; - providing a flow cytometric sperm sorting device selected from the in-air droplet systems and the flow cell tip close systems; - using a sperm sorting device on said labelled fluid mixture employing a high energy emitting light source regarding the specific excitation spectrum of the dye, thereby providing each spermatozoon encased in a single droplet of fluid which is hydrodynamically oriented by the use of sheath fluid, identifying the DNA content of said droplet of fluid, assigning an electric charge corresponding to the chromosome status of said droplet and sorting said droplet; and directing said droplet by electrostatic deflection into one of separate collected tubes each containing a catch fluid, wherein the sample fluid and/or the catch fluid comprises liposomes and/or at least one inhibitor of Slo3 potassium channel.

9. 发明申请

WO2023011635A1 NEW TREATMENT OF IMMUNODEFICIENCY DISORDER 审中-公开
公开(公告)号：WO2023011635A1
公开(公告)日：2023-02-09
申请号：PCT/CN2022/110573
申请日：2022-08-05
申请人： ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD.
发明人： SAMUELSSON, Bengt Ingemar
IPC分类号： A61K31/47 , A61P1/00 , A61P1/16 , A61P29/00 , A61P37/04 , A61P17/02 , A61P43/00
摘要： The use of montelukast or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an immunodeficiency disorder and also for the treatment of a disorder characterized by inflammation in a patient that has, or is vulnerable to, a condition characterized by immunosuppression. Particular disorders that may be mentioned include those brought on by radiation therapy as part of e.g. cancer treatment, such as radiation proctitis. Montelukast and salts thereof are preferably administered topically and locally, for example anorectally.

10. 发明申请

WO2023285654A2 COMPOUNDS FOR THE TREATMENT OF COVID-19 审中-公开
公开(公告)号：WO2023285654A2
公开(公告)日：2023-01-19
申请号：PCT/EP2022/069860
申请日：2022-07-15
申请人： DOMPE' FARMACEUTICI SPA , FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V.
发明人： BECCARI, Andrea Rosario , IACONIS, Daniela , MANELFI, Candida , TALARICO, Carmine , ZUZIKOV, Maria , GRIBBON, Philip , GEISSLINGER, Gerd , ZALIANI, Andrea
IPC分类号： A61K31/529 , A61K31/04 , A61K31/136 , A61K31/155 , A61K31/164 , A61K31/343 , A61K31/352 , A61K31/404 , A61K31/428 , A61K31/47 , A61K31/473 , A61K31/55 , A61K31/7056 , A61P31/14
摘要： The present invention relates to compounds for the treatment of a SARS-CoV-2 infection and/or COVID-19 in a subject.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式